Sign up for the Word on the Tree newsletter

For the second time, U.S. Rep. Tom Marino (R-Pa.) is being considered to head the Office of National Drug Control Policy. The news that Marino, 65, was President Trump’s choice for the drug czar post came four months after he withdrew his name due to a “critical illness” in his family.

Marino has a sketchy track record. In 2007, when he was U.S. attorney in the Middle District of Pennsylvania, he resigned abruptly during a Justice Department investigation for abuse of authority. In 1998, he was accused of “judge-shopping” when trying to get a friend’s cocaine-dealing conviction expunged; according to court records, he hand-delivered an expungement request to a judge three weeks after a different judge had refused it. He was elected to Congress in 2010 from a largely rural district in the state’s northeast.

“The only way I would agree to consider legalizing marijuana is if we had a really in-depth study,” Marino said last October. “If it does help people one way or the other, then produce it in pill form. But don’t make an excuse because you want to smoke marijuana.”

Marino has also repeatedly voted against the Rohrabacher-Farr amendment (now known as Rohrabacher-Blumenauer), which protects state medical-marijuana programs from federal interference. He also voted against a bill that would have allowed Veterans Administration doctors to recommend medical marijuana in states where it’s legal.

“He’s a disastrous choice for drug czar and needs to be opposed,” says Bill Piper, Drug Policy Alliance’s senior director of national affairs. “Our nation needs a drug czar who wants to treat drug use as a health issue, not someone who wants to double down on mass incarceration.”

The Senate can confirm Marino with only a simple majority vote.

This post was originally published at Check out Freedom Leaf magazine for this editor’s Word on the Tree column.

Sign up for Word on the Tree's daily email newsletter

The Word on the Tree newsletter is widely hailed by cannabis professionals, advocates, and journalists as indispensable reading. Get updates on policy reform, business dealings, and scientific research – all in a concise digest.